Protein Tyrosine Kinases
From Inhibitors to Useful Drugs
Seiten
2010
|
Softcover reprint of hardcover 1st ed. 2006
Humana Press Inc. (Verlag)
978-1-61737-534-7 (ISBN)
Humana Press Inc. (Verlag)
978-1-61737-534-7 (ISBN)
Features leading researchers, from the Novartis group who comprehensively survey the developments in the drug discovery processes (bio- and chemoinformatics, structural biology, profiling, generation of resistance, and more) aimed at generating PTK inhibitors for the treatment of various diseases, including cancer.
Leading researchers, from the Novartis group that pioneered Gleevec/Glivec™ and around the world, comprehensively survey the state of the art in the drug discovery processes (bio- and chemoinformatics, structural biology, profiling, generation of resistance, etc.) aimed at generating PTK inhibitors for the treatment of various diseases, including cancer. Highlights include a discussion of the rationale and the progress made towards generating "selective" low molecular-weight kinase inhibitors; an analysis of the normal function, role in disease, and application of platelet-derived growth factor antagonists; and a summary of the factors involved in successful structure-based drug design. Additional chapters address the advantages and disadvantages of in vivo preclinical models for testing protein kinase inhibitors with antitumor activity and the utility of different methods in the drug discovery and development process for determining "on-target" vs "off-target" effects of kinase inhibitors.
Leading researchers, from the Novartis group that pioneered Gleevec/Glivec™ and around the world, comprehensively survey the state of the art in the drug discovery processes (bio- and chemoinformatics, structural biology, profiling, generation of resistance, etc.) aimed at generating PTK inhibitors for the treatment of various diseases, including cancer. Highlights include a discussion of the rationale and the progress made towards generating "selective" low molecular-weight kinase inhibitors; an analysis of the normal function, role in disease, and application of platelet-derived growth factor antagonists; and a summary of the factors involved in successful structure-based drug design. Additional chapters address the advantages and disadvantages of in vivo preclinical models for testing protein kinase inhibitors with antitumor activity and the utility of different methods in the drug discovery and development process for determining "on-target" vs "off-target" effects of kinase inhibitors.
Protein Tyrosine Kinases as Targets for Cancer and Other Indications.- Inhibitors of Signaling Interfaces.- PI3-Kinase Inhibition.- Src as a Target for Pharmaceutical Intervention.- Activated FLT3 Receptor Tyrosine Kinase as a Therapeutic Target In Leukemia.- JAK Kinases in Leukemias, Lymphomas, and Multiple Myeloma.- Glivec® (Gleevec®, Imatinib, STI571).- Platelet-Derived Growth Factor.- Structural Biology of Protein Tyrosine Kinases.- Testing of Signal Transduction Inhibitors in Animal Models of Cancer.- Phosphoproteomics in Drug Discovery and Development.
| Erscheint lt. Verlag | 1.12.2010 |
|---|---|
| Reihe/Serie | Cancer Drug Discovery and Development |
| Zusatzinfo | XIII, 290 p. |
| Verlagsort | Totowa, NJ |
| Sprache | englisch |
| Maße | 152 x 229 mm |
| Themenwelt | Naturwissenschaften ► Biologie ► Biochemie |
| Naturwissenschaften ► Biologie ► Mikrobiologie / Immunologie | |
| ISBN-10 | 1-61737-534-9 / 1617375349 |
| ISBN-13 | 978-1-61737-534-7 / 9781617375347 |
| Zustand | Neuware |
| Haben Sie eine Frage zum Produkt? |
Mehr entdecken
aus dem Bereich
aus dem Bereich
